Re: ABBV/ENTA US HCV scripts/week ending 1/26/18 (IMS)
ABBV/ENTA’s new-patient share (NRx) reached 35.6%, the highest-ever level reported by IMS. (Almost all of ABBV/ENTA’s US patient share is now coming from Mavyret.) ABBV/ENTA’s total-patient share (TRx) reached 29.3%.
The actual Mavyret figures reported by IMS for the week ending 1/26/18 are:
NRx 951 (+21% vs prior week) TRx 1607 (+17% vs prior week)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”